Groupe d'Etude en Oncologie du Quebec

Titre	Phase II Study to Assess the Safety of Non-operative Management for Low Rectal Cancer
Protocole ID	PJT - 148730 (NOM - rectal cancer)
ClinicalTrials.gov ID	NCT03179540
Type(s) de cancer	Colorectal
Phase	Phase II
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL SAINT-FRANCOIS D'ASSISE 10 Rue de l'Espinay, Québec, QC, G1L 3L5
Ville	Québec
Investigateur(trice) principal(e)	Dr Sébastien Drolet
Coordonnateur(trice)
Statut	Actif en recrutement
Critètes d'éligibilité	Completed chemoradiotherapy (CRT) as standard of care [Stage II and Stage III (T3-T4N0, AnyTN1-2)]; [50 Gy (2 Gy x 25 fractions) with 5-FU or capecitabine] Planned or probable APR ALL criteria for complete clinical response are met between 8 and 10 weeks following completion of CRT 18 years or older Provides written consent
Critètes d'exclusion	Unable to undergo MRI Metastatic disease (including extramesorectal and retroperitoneal lymph nodes) Pregnancy Inflammatory bowel disease More than one primary colorectal cancer Other malignancy within 5 years of treatment for current rectal cancer Unfit for surgery

Groupe d'étude en oncologie du Québec